Focusing on the KEYNOTE-B61 trial evaluating lenvatinib plus pembrolizumab in the first line, a panel of medical oncologists react to clinical trial data on combination regimens in non–clear cell renal cell carcinoma.
Mainstreaming of Genetic Testing Is Tied to Increased Testing Rates in Ovarian Cancer
FDA Approval Insights: Cilta-Cel in R/R Myeloma After at Least 1 Prior Line of Therapy
Cilta-Cel Allows for Treatment-Free Period in Early R/R Multiple Myeloma
Expert Insights on the United States Chemotherapy Shortage
Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma
Yale Cancer Center Experts Present New Research on Obesity, Tobacco, Evolution, and Early Onset Cancers at Leading Oncology Conference
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma